Cargando…
Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy
Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver dam...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754839/ https://www.ncbi.nlm.nih.gov/pubmed/36531832 http://dx.doi.org/10.1155/2022/4291758 |
_version_ | 1784851289616678912 |
---|---|
author | Shiri Aghbash, Parisa Ebrahimzadeh Leylabadlo, Hamed Fathi, Hamidreza Bahmani, Mohaddeseh Chegini, Rojin Bannazadeh Baghi, Hossein |
author_facet | Shiri Aghbash, Parisa Ebrahimzadeh Leylabadlo, Hamed Fathi, Hamidreza Bahmani, Mohaddeseh Chegini, Rojin Bannazadeh Baghi, Hossein |
author_sort | Shiri Aghbash, Parisa |
collection | PubMed |
description | Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease. |
format | Online Article Text |
id | pubmed-9754839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-97548392022-12-16 Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy Shiri Aghbash, Parisa Ebrahimzadeh Leylabadlo, Hamed Fathi, Hamidreza Bahmani, Mohaddeseh Chegini, Rojin Bannazadeh Baghi, Hossein Can J Gastroenterol Hepatol Review Article Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease. Hindawi 2022-12-08 /pmc/articles/PMC9754839/ /pubmed/36531832 http://dx.doi.org/10.1155/2022/4291758 Text en Copyright © 2022 Parisa Shiri Aghbash et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Shiri Aghbash, Parisa Ebrahimzadeh Leylabadlo, Hamed Fathi, Hamidreza Bahmani, Mohaddeseh Chegini, Rojin Bannazadeh Baghi, Hossein Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
title | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
title_full | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
title_fullStr | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
title_full_unstemmed | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
title_short | Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy |
title_sort | hepatic disorders and covid-19: from pathophysiology to treatment strategy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9754839/ https://www.ncbi.nlm.nih.gov/pubmed/36531832 http://dx.doi.org/10.1155/2022/4291758 |
work_keys_str_mv | AT shiriaghbashparisa hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT ebrahimzadehleylabadlohamed hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT fathihamidreza hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT bahmanimohaddeseh hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT cheginirojin hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy AT bannazadehbaghihossein hepaticdisordersandcovid19frompathophysiologytotreatmentstrategy |